Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05619497 · ClinicalTrials.gov registry record · NA

The OPENS Trial: Offering Women PrEP (Aim 2)

A NA study of Human Immunodeficiency Virus and Sexually Transmitted Diseases, sponsored by University of California, San Francisco.

Completed
Registry status
NA
Development phase
141
Enrollment target
1
Study location

NCT05619497: Completed NA study of Human Immunodeficiency Virus and Sexually Transmitted Diseases, sponsored by University of California, San Francisco.

NCT05619497 is a NA study of Human Immunodeficiency Virus and Sexually Transmitted Diseases that has completed, run by University of California, San Francisco. The registered enrollment target is 141 participants, below the 180-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05619497, a NA study of Human Immunodeficiency Virus and Sexually Transmitted Diseases, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
NA
Development phase
141 participants
Enrollment target
1
Study location

Study Summary

To address the significant barriers to pre-exposure prophylaxis (PrEP) implementation for cisgender women and address racial inequities in HIV prevention in the United States (US), a novel approach that accounts for multilevel influences is necessary. This study is the second part (Aim 2) of a multi-component project and involves a patient- and clinic-level intervention in a public health family planning clinic in Duval County Florida, where most patients are women of color. The area has one of the highest HIV incidence rates among women in the US. The investigators developed 1) a tablet-based decision support tool (DST) that helps users learn about HIV vulnerabilities and HIV prevention strategies to inform how they consider options for reducing their likelihood of acquiring HIV, and 2) clinic-wide trainings regarding shared decision making and trauma informed care. In Aim 1 (previously completed), participants were randomized to viewing an HIV prevention DST in a clinic that had not received clinic-wide trainings. In Aim 2 (the present study), there will be two phases. In the first phase, participants will receive care at the clinic following training; the DST will not be used. In the second phase, in addition to being seen at a clinic-site that has experienced the training, participants will use the DST before their visit. Participants will be surveyed about experiences with HIV prevention counseling, intentions about using HIV prevention, and DST use (among those in the active arm in the second phase). A subset of participants, individuals who self-identify as Black or Latinx, will also complete a post-clinic visit interview. The investigators will assess whether participants initiated an HIV prevention method three months following their initial visit. The main outcomes will include a quantitative and qualitative assessment of PrEP or other HIV prevention use, decisional certainty, and satisfaction with information about HIV prevention options.

Primary Outcome

The number of participants who received a PrEP prescription within 3 months of their baseline visit, obtained by chart extraction from the medical record. Outcome is dichotomous (Yes, received a PrEP prescription at initial visit/No, did not receive a PrEP prescription at initial visit).

Interventions

  • OTHER Clinic-wide Trainings
  • OTHER Clinic-wide Trainings and HIV Prevention Decision Support Tool (DST)
  • OTHER Standard Care with the HIV Prevention Decision Support Tool (DST)

Study Locations (1)

Florida

  • Florida Department of Health, Duval County - Jacksonville

Trial Details

FieldValue
Enrollment Target 141 participants
Start Date 2022-12-02
Est. Completion 2024-11-01
Phase NA

What the finished NCT05619497 record still lists

NCT05619497 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, below the 180-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (22% lower).

The record links to 3 conditions, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 3 interventions - of which Clinic-wide Trainings is the first listed.

NCT05619497 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT05619497 about?

NCT05619497 is a clinical study titled "The OPENS Trial: Offering Women PrEP (Aim 2)". To address the significant barriers to pre-exposure prophylaxis (PrEP) implementation for cisgender women and address racial inequities in HIV prevention in the United States (US), a novel approach that accounts for multilevel influences is necessary. This study is the second part (Aim 2) of a multi...

What is the current status of trial NCT05619497?

This trial is currently completed. It is a NA study. The enrollment target is 141 participants. The study started on 2022-12-02. Estimated completion is 2024-11-01.

What conditions does trial NCT05619497 study?

This clinical trial studies the following conditions: Human Immunodeficiency Virus, Sexually Transmitted Diseases, Human Immunodeficiency Virus Transmission.

What interventions are being tested in trial NCT05619497?

The interventions under investigation include: Clinic-wide Trainings (OTHER), Clinic-wide Trainings and HIV Prevention Decision Support Tool (DST) (OTHER), Standard Care with the HIV Prevention Decision Support Tool (DST) (OTHER).

Who is sponsoring clinical trial NCT05619497?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05619497 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Human Immunodeficiency Virus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05619497's enrollment target sits among peer trials

141 14th of 39 higher than 26 of 39 other Human Immunodeficiency Virus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Human Immunodeficiency Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03042962 · 141 participants

    Brain Networks in Dystonia

  • NCT04378439 · 141 participants · NA

    Appalachian Partnership to Reduce Disparities (Aim 2)

  • NCT04775485 · 141 participants · Phase 2

    A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

  • NCT05040360 · 141 participants · Phase 2

    Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05619497, the US trial registry maintained by the National Library of Medicine. NCT05619497 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.